Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of June 24, Anjiasi's closing price was 63.18 yuan, reflecting a 1.31% increase, with a rolling price-to-earnings (PE) ratio of 17.23 times and a total market capitalization of 5.116 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, positioning Anjiasi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjiasi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjiasi's main products include GI series, EMR/ESD series, ERCP diagnostic series, and therapeutic instruments, contributing to its revenue growth [1] - The latest financial report for the first quarter of 2025 shows Anjiasi achieved an operating income of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]

得成为激励对象的下列情形： （1）最近12 个月内被证券交易所认定为不适当人选； （2）最近12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 杭州安杰思医学科技股份有限公司 监事会关于公司2025年限制性股票激励计划 授予激励对象名单的核查意见（截至授予日） 杭州安杰思医学科技股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）、《科创板上市公司自律监管指南第4 号——股权激励信 息披露》等法律、法规及规范性文件和《杭州安杰思医学科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，对公司2025年限制性股票激励计 划（以下简称"本激励计划"）授予激励对象名单（截至授予日）进行审核， 发表核查意见如下： （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形 ...

Meeting Overview - The third meeting of the Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The Supervisory Board approved the proposal to grant restricted stock to three eligible incentive objects under the 2025 Restricted Stock Incentive Plan at a price of 46.16 yuan per share, totaling 16,089 shares [1][2]. - The Supervisory Board approved the proposal to postpone certain fundraising investment projects, stating that the decision was made based on the actual construction situation and did not harm shareholders' interests [2]. - The Supervisory Board approved the use of self-owned foreign exchange funds to pay for the required funds for fundraising projects, with a plan to replace the amount with raised funds, ensuring compliance with relevant regulations and improving fund utilization efficiency [3].

Core Viewpoint - The company has adjusted the cash dividend per share for the 2024 annual profit distribution from RMB 13.8000 to RMB 13.7350 due to changes in the number of shares eligible for distribution following a transfer of shares to an employee stock ownership plan [1][2][3] Summary by Sections Adjustment of Cash Dividend - The cash dividend per 10 shares has been adjusted from RMB 13.8000 (including tax) to RMB 13.7350 (including tax) [1] - The adjustment was necessary due to the transfer of 381,423 shares from the company's repurchase account to the employee stock ownership plan, affecting the number of shares eligible for the profit distribution [1][2] Previous Profit Distribution Plan - The original profit distribution plan approved on April 21, 2025, proposed a cash dividend of RMB 13.8000 per 10 shares, with a total cash dividend of RMB 111,196,116.48 (including tax) based on a total eligible share count of 80,576,896 shares [1][2] Revised Profit Distribution Plan - After the adjustment, the total number of shares eligible for profit distribution is now 80,958,319 shares, maintaining the total cash dividend amount at RMB 111,196,116.48 (including tax) [3] - The adjusted cash dividend per share is calculated as approximately RMB 1.3735 (including tax), leading to a total cash distribution of approximately RMB 111,196,251.15 (including tax) [3]

2025 年 6 月 19 日，公司收到中国证券登记结算有限责任公司出具的《证券 过户登记确认书》，公司回购专用证券账户中所持有的 381,423 股公司股票已于 2025 年 6 月 19 日非交易过户至"杭州安杰思医学科技股份有限公司-2025 年员 工持股计划"证券账户（证券账户号码：B887331540），过户价格为 32.97 元/ 股。截至本公告披露日，本员工持股计划证券账户持有公司股票 381,423 股，占 公司总股本的比例为 0.4710%。 证券代码：688581 证券简称：安杰思 公告编号：2025-042 杭州安杰思医学科技股份有限公司 关于 2025 年员工持股计划非交易过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日 分别召开第二届董事会第十九次会议和第二届监事会第十五次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，审议通过了《关于公司 2025 年员工持股 计划（草案）及 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-043 杭州安杰思医学科技股份有限公司 如在利润分配预案公告披露之日起至实施权益分派股权登记日期间，因可转 债转股/回购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等致 使公司总股本（扣减回购专用证券账户的股份）发生变动的，拟维持分配总额不 变，相应调整分配比例，如后续总股本（扣减回购专用证券账户的股份）发生变 化，公司将另行公告具体调整情况。 每股现金分红金额调整情况：杭州安杰思医学科技股份有限公司（以下 简称"公司"）2024 年年度利润分配每 10 股派发现金红利人民币由 13.8000 元（含 税）调整为 13.7350 元（含税） 本次调整原因：根据中国证券登记结算有限责任公司下发的《证券过户 登记确认书》，公司回购专用证券账户中所持有 381,423 股公司股票已非交易过 户至"杭州安杰思医学科技股份有限公司-2025 年员工持股计划"专用证券账户， 致使公司本次可参与本次权益分派的股份数量发生变动。公司按照维持拟分配总 额不变，相应调整分配比例的原则，对 2024 年度利润分配每股现金分红金额进 行相应调整。 一、调整前利 ...

Group 1 - The company held its third board meeting and supervisory board meeting on June 17, 2025, where it approved the use of its own foreign exchange funds to pay for the investment project and to replace it with raised funds [2][7][9] - The company successfully raised a total of RMB 182,032.60 million by issuing 14,470,000 shares at a price of RMB 125.80 per share, with a net amount of RMB 165,101.28 million after deducting issuance costs [2][43][44] - The company plans to use the raised funds for the "Anjisi Thailand Production Base Project" and has established a three-party supervision agreement for the management of the raised funds [3][4][43] Group 2 - The company will use its own foreign exchange funds to pay for part of the investment project during its implementation and will replace these with raised funds later, which is aimed at improving operational efficiency and reducing financial costs [5][6][7] - The company has approved the extension of the "Minimally Invasive Medical Device R&D Center Project" to December 31, 2026, due to the actual construction progress and strategic planning [4][54][55] - The supervisory board and the sponsor have confirmed that the use of foreign exchange funds and the extension of the investment project will not affect the normal implementation of the investment projects and will not harm the interests of shareholders [8][9][57] Group 3 - The company has established a detailed operational process for the use of its own foreign exchange funds and the subsequent replacement with raised funds, ensuring compliance with relevant regulations [6][8][9] - The company emphasizes the necessity and feasibility of the investment projects, highlighting the importance of technological innovation and talent attraction in maintaining competitive advantages in the medical device industry [46][50][51] - The company believes that the investment projects align with its strategic planning and will continue to monitor conditions for timely adjustments [52][53]

证券代码：688581 证券简称：安杰思 公告编号：2025-039 杭州安杰思医学科技股份有限公司 关于向 2025 年限制性股票激励计划激励对象 授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 杭州安杰思医学科技股份有限公司（以下简称"公司"）2025 年限制性股 票激励计划（以下简称"激励计划"）规定的限制性股票授予条件已成就，根据 2024 年年度股东大会的授权，公司于 2025 年 06 月 17 日召开第三届董事会第二 次会议、第三届监事第二次会议，审议通过了《关于向 2025 年限制性股票激励 计划激励对象授予限制性股票的议案》，同意确定 2025 年 06 月 17 日为授予日， 向符合授予条件的 3 名激励对象授予 16,089 股限制性股票，授予价格为 46.16 元/股。 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 限制性股票授予日：2025 年 06 月 17 日 限制性股票授予数量：16,089 股，约占目前公司股本总额 8 ...

杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划授予激励对象名单 3、本激励计划中部分合计数与各明细数相加之和在尾数上如有差异，系以上百分比结果四舍五入所致。 杭州安杰思医学科技股份有限公司董事会 2025 年 06 月 17 日 | | | | | 获授的限制 性股票占本 | 获授的限制 性股票占本 | | --- | --- | --- | --- | --- | --- | | | | | 获授的限制 | 激励计划拟 | 激励计划草 | | 姓名 | 国籍 | 职务 | 性股票数量 （股） | 授出限制性 | 案公布日股 | | | | | | 股票总量的 | 本总额的比 | | | | | | 比例 | 例 | | 核心管理人员及核心技术（业务）人员 人） | （3 | | 16089 | 100.00% | 0.02% | | 合计 | | | 16089 | 100.00% | 0.02% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司总股本的 1.00%，公司 全部有效期内的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会 ...

北京德恒（杭州）律师事务所 关于 杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划授予相关事项的 法律意见 电话:0571-86508080 传真:0571-87357755 邮编:31001 浙江省杭州市上城区新业路 200 号华峰国际大厦 10 楼 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划授予相关事项的法律意见 北京德恒（杭州）律师事务所 关于 杭州安杰思医学科技股份有限公司 | 一、 本激励计划授予事项的批准和授权 5 | | --- | | 二、 本激励计划授予的授予日 7 | | 三、 本激励计划的授予条件 7 | | 四、 本激励计划授予的对象、价格和数量 8 | | 五、 结论意见 9 | 为出具本法律意见，本所律师特作出声明如下： 德恒 12F20250152-2 号 致：杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划授予相关事项的 法律意见 1. 本所律师承诺依据本法律意见出具日以前已经发生或存在的、与本激励 计划有关的事实，根据安杰思提供的文件以及我国现行法律法规及中国证监会的 有关规定发表法律意见； 2. ...